ABSTRACT
Background and aims There is growing evidence that tobacco smoking causes depression, but it is unclear which constituents of tobacco smoke (e.g., nicotine, carbon monoxide) may be responsible. We used Mendelian randomisation (MR) to examine the independent effect of nicotine on depression, by adjusting the effect of nicotine exposure (via nicotine metabolite ratio [NMR]) for the overall effect of smoking heaviness (via cigarettes per day [CPD]) to account for the non-nicotine constituents of tobacco smoke.
Design Univariable MR and multivariable MR (MVMR) were used to explore the total and independent effects of genetic liability to NMR and CPD on major depressive disorder (MDD). Our primary method was inverse variance weighted (IVW) regression, with other methods as sensitivity analyses.
Setting and participants For the exposures, we used genome-wide association study (GWAS) summary statistics among European ancestry individuals for CPD (n=143,210) and NMR (n=5,185). For the outcome, a GWAS of MDD stratified by smoking status was conducted using individual-level data from UK Biobank (n=35,871-194,881).
Measurements Genetic variants robustly associated with NMR and CPD.
Findings Univariable MR indicated a causal effect of CPD on MDD (odds ratio [OR]IVW=1.13, 95% confidence interval [CI]=1.04-1.23, P=0.003) but no clear evidence for an effect of NMR on MDD (ORIVW=0.98, 95% CI=0.97-1.00, P=0.134). MVMR indicated a causal effect of CPD on MDD when accounting for NMR (ORMVMR-IVW=1.19, 95% CI=1.03-1.37, P=0.017; ORMVMR-EGGER=1.13, 95% CI=0.89-1.43, P=0.300) and weak evidence of a small effect of NMR on MDD when accounting for CPD (ORMVMR-IVW=0.98, 95% CI=0.96-1.00, P=0.056; ORMVMR-EGGER=0.98, 95% CI=0.96-1.00, P=0.038).
Conclusions The causal effect of tobacco smoking on depression appears to be largely independent of nicotine exposure, which implies the role of alternative causal pathways.
Competing Interest Statement
GT has previously received funding from Grand (Pfizer) for work not related to this project. CB, HS and RW have completed paid consultancy work for Action on Smoking and Health (ASH) for work related to this project. There are no other conflicts of interest to declare.
Clinical Protocols
Funding Statement
This project is funded by a Society for the Student of Addiction PhD studentship awarded to CB. The funding body had no role the design of the study or collection, analysis, and interpretation of data, or in writing this manuscript. REW is funded by a postdoctoral fellowship from the South-Eastern Norway Regional Health Authority (2020024). This work is supported by the Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol (MC_UU_00032/07). JK receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under the grant agreement No. 777394 for the project AIMS-2-TRIALS. This work was supported by Cancer Research UK (grant number C18281/A29019) who funded the salary of JK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank received ethics approval from the North West Multi-Centre Research Ethics Committee as a Research Tissue Bank approval (REC; 11/NW/0382). Approval to use these data was sought and approved by UK Biobank (Project ID: 9142).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Christina Dardani and Jasmine Khouja to be considered as joint senior author
Data Availability
Data and code required to replicate the analysis findings reported in the article are provided on GitHub at: https://doi.org/10.5281/zenodo.12187311. Primary data from the UK Biobank resource are accessible upon application (https://www.ukbiobank.ac.uk/). The summary level data sets used for the exposures in MR analyses are available online; GSCAN (https://conservancy.umn.edu/items/ca7ed549-636b-41c0-ae79-97c57e266417); Buchwald and colleagues (https://www.ebi.ac.uk/gwas/efotraits/EFO_0007794).
https://doi.org/10.5281/zenodo.12187311
https://conservancy.umn.edu/items/ca7ed549-636b-41c0-ae79-97c57e266417
